The Globe and Mail14d
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...
Nasdaq14d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...
Yahoo Finance15d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
조선일보21d
U.S. investors pivot to Chinese biotech firms for cost-effective drug development
U.S. company Merck (MSD) signed an exclusive license agreement for the obesity treatment 'HS-10535' with Chinese pharmaceutical corporation Hansoh Pharmaceuticals last December. This is a large ...
americanbazaaronline.com22d
Big Pharma turns to China for future deals
Merck & Co. signed an exclusive global license agreement with Chinese pharmaceutical company Hansoh Pharma for HS-10535, an oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed as ...
Hosted on MSN25d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
The company has penned a deal to develop a potential GLP-1 weight loss therapy, HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the ...